Trial Profile

An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary) ; Melphalan flufenamide (Primary)
Indications Amyloid light-chain amyloidosis
Focus Adverse reactions; Therapeutic Use
Acronyms ASCENT
Sponsors Oncopeptides

Most Recent Events

03 Feb 2022 Status changed from active, no longer recruiting to discontinued.
16 Dec 2021 This trial has been discontinued in Germany, according to European Clinical Trials Database record.
04 Dec 2021 This trial has been discontinued in Poland according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com